Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 18;392(10147):593-606.
doi: 10.1016/S0140-6736(18)31041-9. Epub 2018 Aug 2.

Acute myeloid leukaemia

Nicholas J Short  1 , Michael E Rytting  2 , Jorge E Cortes  3
Affiliations
Review

Acute myeloid leukaemia

Nicholas J Short et al. Lancet. .

Abstract

For several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen in the number of drugs available for the treatment of acute myeloid leukaemia, with several new drugs receiving regulatory approval. In addition to advancing our therapeutic armamentarium, an increased understanding of the biology and genomic architecture of acute myeloid leukaemia has led to refined risk assessment of this disease, with consensus risk stratification guidelines now incorporating a growing number of recurrent molecular aberrations that aid in the selection of risk-adapted management strategies. Despite this promising recent progress, the outcomes of patients with acute myeloid leukaemia remain unsatisfactory, with more than half of patients ultimately dying from their disease. Enrolment of patients into clinical trials that evaluate novel drugs and rational combination therapies is imperative to continuing this progress and further improving the outcomes of patients with acute myeloid leukaemia.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests

We declare no competing interests.

Figures

Figure 1:
Figure 1:. Management of acute myeloid leukaemia in adults
HLA=human leukocyte antigen. HSCT=haemopoietic stem cell transplant.
Figure 2:
Figure 2:. Examples of selected novel therapeutic strategies in acute myeloid leukaemia
Five therapeutic targets being developed for the management of acute myeloid leukaemia are highlighted, as well as representative compounds that are in clinical trials. These examples are not intended to be all inclusive. Strategies that eliminate leukaemia stem cells, which are generally chemoresistant and serve as a reservoir for relapse, are needed to achieve cure.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ganzel C, Manola J, Douer D, et al. Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN Cancer Research Group trials, 1980–2008. J Clin Oncol 2016; 34: 3544–53. - PMC - PubMed
    1. Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in adults with acute leukemia. Blood 2012; 120: 1993–2002. - PubMed
    1. National Cancer Institute. Cancer stat facts: leukemia—acute myeloid leukemia (AML). 2017. https://seer.cancer.gov/statfacts/html/amyl.html (accessed Sept 21, 2017).
    1. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer 2017; 17: 513–277. - PMC - PubMed
    1. Leonard JP, Martin P, Roboz GJ. Practical implications of the 2016 revision of the World Health Organization classification of lymphoid and myeloid neoplasms and acute leukemia. J Clin Oncol 2017; 35: 2708–15. - PubMed

MeSH terms